Joseph J. Eron

TL;DR: The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d. regimen and an APV- RTV 1200/200 mg q.d.) regimen studied in a human immunodeficiency virus (HIV)-infected population were well tolerated, which supports APV/RTV as an option for twice-daily or daily therapy for HIV.

TL;DR: D dose separation and increased doses of RTV are investigated as a means to overcome the interaction between FPV and LPV/RTV in both human immunodeficiency virus (HIV)-infected patients and seronegative volunteers to determine the optimal dosing of FPV with LPV-RTV.

TL;DR: This study challenges current thinking about federal regulations’ group-based approach to defining vulnerable populations and identifies barriers affecting HIV/AIDS researchers’ ability to conduct clinical trials with pregnant women, prisoners, and children.

TL;DR: Characteristics of patients for whom treatment was strongly to moderately recommended but who did not initiate ART within two years of entering care are identified to provide a target for closer monitoring and intervention to reduce disparities in HIV care.

TL;DR: A useful conceptual and methodological framework for using observational data to appropriately evaluate the impact on HIV racial/ethnic disparities of interventions and reframes relevant scientific questions in terms of a controlled direct effect and estimates a corresponding proportion eliminated is described.